Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.

This study found that long-term use of a home-use LED device for neck skin rejuvenation significantly improved wrinkle appearance and skin biophysical parameters without affecting thyroid function or morphology after 16 weeks of daily use.

This review covers the current status of the interstitial pneumonia with autoimmune features (IPAF) category, pointing out the need for revision of its criteria to establish it as a standalone diagnostic term, but reports no new clinical findings.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This study found that topical metformin was as effective as triple combination cream in reducing melasma severity, with minimal adverse events.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

This review discusses the growing role of colorimetric sensors in food safety, highlighting their potential to enhance detection accuracy and manageability, while also noting challenges such as environmental interference and the need for further industrial validation.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

This review reports limited evidence suggesting that stem cell-based therapies, particularly using human-derived mesenchymal stem cells and exosomes, may be effective for skin rejuvenation, though results are uncertain due to methodological limitations and variability across studies.

This review discusses the potential benefits and challenges of using extracellular vesicles in aesthetic medicine but reports no new clinical results, highlighting the need for rigorous validation and stronger regulatory oversight.

In this randomized, double-blind, placebo-controlled trial, topical 3% minoxidil was found to significantly improve facial hair density and diameter, quality of life, and patient satisfaction in transgender men on stable gender-affirming hormone therapy, with minimal adverse events compared to placebo.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

Single-needle radiofrequency is effective and safe for treating facial sebaceous hyperplasia.

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

This study assessed the combination of compound glycyrrhizin and conventional treatments for alopecia areata and found it effective for promoting hair regrowth while being safe with mild adverse effects, based on a systematic review and meta-analysis of randomized controlled trials.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia, although more mild adverse events were reported compared to minoxidil alone.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study found that ablative fractional carbon dioxide laser treatment improved skin fibrosis, reduced skin hardening, and enhanced hair follicle growth in localized scleroderma patients, with significant improvements across several clinical measures and no severe adverse effects observed.

In this study, the combination of topical minoxidil and betamethasone was found to be more effective for hair regrowth and patient satisfaction in alopecia areata patients compared to betamethasone alone or with herbal oils, though further randomized trials are recommended.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

This systematic review found that light and laser therapies, including excimer and erbium-glass lasers, generally increase hair density and diameter in various types of alopecia, with particularly notable effects in androgenic alopecia but limited efficacy in telogen effluvium.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this study, researchers observed that after 5 years of treatment, 89.9% of Korean men with androgenetic alopecia experienced improvement and 93.9% had prevention of disease progression with dutasteride 0.5mg, though sexual-related symptoms were common early but subsided over time.

This study suggests that platelet-rich plasma is a safe and effective treatment for alopecia areata, showing superior treatment response compared to triamcinolone acetonide and placebo, with primarily minor side effects.

This article examines the morphological and physiological characteristics of eyelash follicles and offers clinical management suggestions for conditions like eyelash loss and trichomegaly, but presents no new clinical results.